ReviewCancer metastasis reviews2025
Socioeconomic impact of artificial intelligence-driven point-of-care testing devices for liquid biopsy in the OncoCheck system.
Review in Cancer metastasis reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial intelligence-enabled liquid biopsy in cancer: a systematic review and meta- analysis of diagnostic performance and biological implications.Frontiers in oncology · 2026Pooled it
- Electrochemical liquid biopsy across cancer care pathway.The journal of liquid biopsy · 2026Review
- Artificial intelligence-powered liquid biopsy in cancer: a paradigm shift in cancer detection and personalized care.Cancer cell international · 2026Review
- Liquid biopsy in breast cancer: current biomarker platforms and clinical applications.Exploration of targeted anti-tumor therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cancer disparities in low- and middle-income countries (LMICs) persist because of socioeconomic inequalities and limited access to screening infrastructure, which requires equitable diagnostic solutions. As researchers, we need to develop interventions which mirror successful strategies from high-income countries (HICs) to address mortality inequalities. Routine cancer diagnosis functions as a fundamental element of effective management yet remains unavailable to numerous populations in LMICs. This review proposes the conceptual "OncoCheck" model, which combines the terms Oncology "Onco" and Screening "Check" as an integrated approach to early cancer detection. It provides a theoretically sound practical approach that combines liquid biopsy with point-of-care testing (POCT) and artificial intelligence (AI) to achieve high-sensitivity diagnostics in resource-limited settings without requiring advanced infrastructure. The review advocates OncoCheck as a promising and practical cancer screening solution which shows potential to increase accessibility and decrease costs while improving survival rates through early detection. Moving beyond technical specifications, the manuscript assesses its socioeconomic impact, showing reduced medical costs and improved treatment outcomes. The paper describes its implementation framework together with a validation strategy and performance benchmarks. The analysis further focuses on the implementation barriers like algorithmic bias mitigation, infrastructure limitations, and ethical AI deployment. The OncoCheck system delivers equitable cancer care by implementing a hospital-at-home model which functions with real-world health systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.